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INTRODUCTION
On 12 September 2011, the US National Human Genome 
Research Institute (NHGRI) convened an expert working 
group to address the challenges of assigning disease causality 
to sequence variants. Clear guidelines for distinguishing dis-
ease-causing sequence variants from false-positive reports of 
causality were provided.1 The US Centers for Disease Control 
and Prevention2 in the same year and the American College 
of Medical Genetics and Genomics and the Association for 
Molecular Pathology (ACMG) in 2013, concerned about 
accuracy of clinical laboratory reports to clinical practitio-
ners, also convened a workgroup consisting of clinical service 
providers.3
The NHGRI working group cautioned that the vast major-
ity of genes reported as causally linked to monogenic diseases 
are true positives, but 27% of 406 published severe disease 
mutations in 104 sequenced individuals either were common 
polymorphisms or lacked direct evidence for pathogenicity.4–8 
The NHGRI working group defined rare germ-line variants 
with minor allele frequencies of <0.01 that have relatively large 
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Purpose: EFHC1 variants are the most common mutations in inher-
ited myoclonic and grand mal clonic-tonic-clonic (CTC) convulsions of 
juvenile myoclonic epilepsy (JME). We reanalyzed 54 EFHC1 variants 
associated with epilepsy from 17 cohorts based on National Human 
Genome Research Institute (NHGRI) and American College of Medi-
cal Genetics and Genomics (ACMG) guidelines for interpretation of 
sequence variants.
Methods: We calculated Bayesian LOD scores for variants in coinher-
itance, unconditional exact tests and odds ratios (OR) in case–control 
associations, allele frequencies in genome databases, and predictions 
for conservation/pathogenicity. We reviewed whether variants damage 
EFHC1 functions, whether efhc1−/− KO mice recapitulate CTC convul-
sions and “microdysgenesis” neuropathology, and whether supernu-
merary synaptic and dendritic phenotypes can be rescued in the fly 
model when EFHC1 is overexpressed. We rated strengths of evidence 
and applied ACMG combinatorial criteria for classifying variants.
Results: Nine variants were classified as “pathogenic,” 14 as “likely 
pathogenic,” 9 as “benign,” and 2 as “likely benign.” Twenty variants 
of unknown significance had an insufficient number of ancestry-
matched controls, but ORs exceeded 5 when compared with racial/
ethnic-matched Exome Aggregation Consortium (ExAC) controls.
Conclusions: NHGRI gene-level evidence and variant-level evi-
dence establish EFHC1 as the first non–ion channel microtubule–
associated protein whose mutations disturb R-type VDCC and 
TRPM2 calcium currents in overgrown synapses and dendrites 
within abnormally migrated dislocated neurons, thus explaining 
CTC convulsions and “microdysgenesis” neuropathology of JME.
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effects on disease risk and variants that have been implicated in 
severe monogenic diseases and complex diseases.9 The working 
groups’ intended scope excluded common small-effects variants 
typically identified by genome-wide association studies of com-
plex traits.10,11 Because “unambiguous assignment of disease 
causality for sequence variants is often impossible,” the NHGRI 
working group introduced the concept of “implication”—
implicating by genetic evidence sequence variant(s) of a gene 
that is in the process of integrating and assessing experimental 
evidence for pathogenicity.1
For “implication,” the NHGRI workgroup emphasized the 
“critical primacy of strong robust statistical genetic support,” 
such as coinheritance in family studies, case–control associa-
tion studies, allele frequencies in public genome databases, and 
predictions for conservation and pathogenicity. Strong statisti-
cal genetic support for “implication” is then supplemented by 
variant specific experimental studies that demonstrate that a 
gene product is functionally disrupted by variants. The NHGRI 
workgroup values disease models that recapitulate the relevant 
pathology of human disease and allow rescue of the phenotype 
when the molecular disease pathway is knocked out or elimi-
nated.1 The ACMG workgroup, concerned more with reports 
of clinical genomic testing that impact medical decision mak-
ing, took these evidentiary data and rated their strengths as 
“very strong,” “strong,” “moderate,” and “supportive.” They set 
rules for combining the strengths of evidentiary data when 
classifying sequence variants into “pathogenic,” “likely patho-
genic,” “uncertain significance,” “likely benign,” and “benign”3 
(Figure 1).
The NHGRI core guidelines,1 the ACMG consensus recom-
mendations for interpretation of sequence variants,3 and large 
genome databases representing different racial and continen-
tal populations, such as the Genome 1000 (ref. 12), the Exome 
Variant Server 6500 (ref. 13), and the Exome Aggregation 
Consortium (ExAC) (ref. 14), were not available in 2004 when 
variants of the EF-hand domain (C-terminal) containing 1 gene 
(EFHC1) were reported as disease-causing mutations in myo-
clonic and grand mal clonic-tonic-clonic (CTC) convulsions 
produced by juvenile myoclonic epilepsy (JME). Consequently, 
all EFHC1 variants discovered in the first decade of this millen-
nium and reported with respect to epilepsy or not15–28 have not been 
“vetted” through NHGRI and ACMG guidelines. More impor-
tantly, both NHGRI and ACMG guidelines advise that “with evi-
dence on variants evolving” and the “content of sequencing tests 
expanding,” “rigorous evaluation” and “reanalysis of variants are 
encouraged” to prevent misannotation of the pathogenicity of 
variants in public databases. For all these reasons, we applied 
NHGRI guidelines and ACMG rules (Figure 1) for combining 
evidentiary criteria in reanalyzing 54 EFHC1 variants, of which 
33 were originally published as mutations.
MATERIALS AND METHODS
We gathered 54 EFHC1 variants reported in regard to epilepsy 
from scientific and medical literature, bibliographic resources 
from the NCBI PubMed literature server, the ClinVar database,15 
and personal communications with authors of abstracts and post-
ers published during neurological, epilepsy, and genetic meetings. 
The 33 purported EFHC1 mutations are scattered across the 640 
amino acid protein of Myoclonin1 (Figure 2; Supplementary 
Table S1 online places all 54 variants in the GRCh37/hg19 coor-
dinate system, provides rsID number if identified in dbSNP 142, 
and translates the cDNA and protein nomenclature for all four 
coding transcripts identified by Ensembl).
Coinheritance
Twelve families were reported with EFHC1 variants cosegregating 
identically by descent with all disease-affected  members16,17,19,23,25 
and with two variants that did not cosegregate (Table 1). We cal-
culated Bayesian factor linkage likelihood to evaluate the signifi-
cance of sequence variants29 based on the pedigrees as published. 
Eleven different genotyped EFHC1 variants that were found in 
these families were used as marker alleles. JME was assumed to 
be in linkage disequilibrium with the markers and at Ɵ = 0, with 
a standard penetrance model for JME (pnp2 = 0.001; pnpq = 0.7; 
pnq2 = 0.7). We corrected for ascertainment bias as proposed by 
Thompson et al.29
Case–control association studies
Supplementary Table S2 online lists the study design of all 
published case–control studies, their population groups, their 
specific racial/ethnic groups and countries of their residencies, 
the number of index cases and controls, and the targets used in 
screening for EFHC1 mutations in 12 cohorts from 9 countries.
We studied the association of EFHC1 variants with JME or 
genetic generalized epilepsy index cases versus the associa-
tion of EFHC1 variants with ancestry/race-matched controls 
as originally published. Table 2 summarizes the actual results 
of the unconditional exact homogeneity/independence test 
(Z-pooled method, one-tailed),30,31 which assessed whether 
the proportion of variants associated between the two groups 
reflected a statistically significant difference. Supplementary 
Table S3 online provides all the details of the case–control 
studies. Because many of the published studies on EFHC1 had 
insufficient control sample sizes, we also calculated odds ratios 
(OR) and statistical significance (P values) for both the study 
as published and the allele counts available in race-matched 
population groups from the ExAC database.14 An OR of 1.0 
means that the variant does not affect the odds of having the 
disease; values higher than 1.0 indicate that there is an associa-
tion between the variant and the risk for the disease.
Allele frequencies
We extracted the minor allele frequencies for all putative patho-
genic EFHC1 variants in exomes from race-matched and ances-
try-matched presumably normal populations of 6,503 persons 
stored in the 2013 Exome Variant Server13 (ESP6500SI-V2), 
in genome sequences of 2,504 persons of the 1000 Genomes 
Project12 (phase 3, release 16), and in 60,706, exomes col-
lected by the ExAC consortium (Supplementary Table S4a,b 
online).14
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Studies of epilepsy prevalence were selected primarily on the 
basis of whether they classified electroclinical syndromes such 
as genetic generalized epilepsies, JME, and childhood absence 
epilepsy in observed cases. Population prevalence for Hispanics 
was determined by a door-to-door study performed in rural 
Bolivia in 1999.32 Prevalence among Caucasians was deter-
mined by a study of the Norwegian National registry in 2015,33 
and East Asian prevalence by a study of the regional registry of 
patients older than 15 years in Hong Kong, China.34 Another 
estimate of Southeast Asian prevalence was produced via a 
random cluster survey of Cambodian villages.35 Differing in 
methodology and ascertainment and not ideally race-matched 
to JME index cases studied, these studies represent the only 
data we could use to compare allele frequencies of EFHC1 vari-
ants with JME disease prevalence.
Algorithms predicting conservation and pathogenicity
We analyzed the theoretical pathogenicity of all 54 vari-
ants by applying: (i) four algorithms (PhyloP,36,37 SiPhy,38,39 
GERP++,40 and PHASTCons41) that measure evolutionary 
Figure 1 Assigning disease causality to sequence variants according to the National Human Genome Research Institute and American College 
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conservation at the level of DNA base pairs and (ii) seven 
algorithms (SIFT,42,43 PolyPhen2-HVAR,44,45 LRT,46 Mutation 
Taster,47 Mutation Assessor48 and FATHMM,49 and CADD50) 
that calculate amino acid conservation and the likelihood 
of deleteriously  altering the encoded amino acid function 
(Supplementary Table S5a–c online). These algorithms 
were chosen because they were included in the database of 
Nonsynonymous Functional Predictions (dbNSFP v2.6),51,52 
which is available for download from the ANNOVAR53 web-
site. Variants found in non-RefSeq-defined transcripts were 
annotated manually when possible. To determine whether 
variants might affect the splicing consensus, all were run 
through the online algorithms provided by Human Splicing 
Finder.54 To assess the ACMG criterion for benign status 
(BP4), we used the Multiz alignment of 62 mammalian spe-
cies available on the UCSC Genome Browser to determine 
whether the amino acid  substitution would compromise 
function.
Variant-specific experimental functional studies on 
pathogenicity
Only 20 variants have undergone variant-level experimental 
functional studies (Supplementary Table S6a–c online). These 
consist of five EFHC1 mutations and three polymorphisms, which 
we originally reported in 2004 (ref. 16) and 12 EFHC1 mutations 
reported from India (ref. 28). We summarize the results of func-
tional studies in three tables: Supplementary Table S6a online, 
which presents the molecular and cellular models, Table  6b, 
which displays in vivo models of neurodevelopment, and 
Table 6b, which covers the protein–protein interactions (PPIs). 
We also report the level of statistical significance between each 
variant and the wild-type allele published in original articles.55–58
Figure 2 An EF hand–containing calcium-binding gene (EFHC1) spans 72 kb, has 11 exons, three DM10 domains (DM refers to Drosophila 
melanogaster sequences), and one EF-hand motif that is calcium binding (HGNC: 16406). (a) The EFHC1 gene encodes a 640-amino-acid protein called 
myoclonin1. The EF-hand motif is located at the C-terminal between amino acids 578 and 606 and is encoded by a nucleotide sequence that is present in exon 
10. Because the only motif of EFHC1 whose function was known consisted of the EF hand, the gene was first called EFHC1 for “EF hand containing one.”15 The 
diagram shows the domain organization of EFHC1 protein, the positions of various mutations found in JME families, and their frequency (number of independent 
families with a given mutation). Mutation numbering is based on the GenBank reference protein sequence with accession number 608816. A, Africa; B, Brazil; 
DM10, Domain 10; H, Honduras; IN*, India; IS, Israel; IT, Italy; J, Japan; M, Mexico; NY, New York. (b) Schematic representation of an EF-hand motif comprising 
two helixes—E and F—linked by a calcium-binding sequence. Symbolic representation of the same motif as a right hand in which the E helix corresponds to the 
index and the F helix to the thumb. Note: Part b of Figure 2 (EFH domain) has been reproduced with permission (publicly available) from: “http://www.ncbi.nlm.
nih.gov/books/NBK98188/” Myoclonin1/EFHC1 in cell division, neuroblast migration, synapse/dendrite formation in juvenile myoclonic epilepsy. Jasper's Basic 
Mechanisms of the Epilepsies [Internet]. 4th edition. Noebels JL, Avoli M, Rogawski MA, Olsen RW, Delgado-Escueta AV, editors. Bethesda (MD): “http://www.
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Paradigm V—gene level functional studies on pathogenesis
EFHC1 function has been studied at the gene level by knocking 
out EFHC1 orthologs in both mice59,60 and flies (Supplementary 
Table S7 online).61 Both mouse and fly models presented sei-
zure-related and electroclinical phenotypes and neuroanatomi-
cal measures similar to those in the variant-level functional 
studies. These measures and their level of statistical significance 
with respect to the wild type as published are summarized in 
Supplementary Table S7 online.
RESULTS
EFHC1
Ensembl identifies a total of four alternative coding transcripts 
and two noncoding transcripts for EFHC1 (see Supplementary 
Table S1 online). Most reported EFHC1 variants associated with 
epilepsies cause amino acid substitutions in two of the isoforms: 
transcripts A (length: 640aa) and B (length: 278aa). The two tran-
scripts share the first 241-amino-acid sequence, and transcript 
B translates two additional variants, causing a frameshift and 
nonsense change in the protein, but it is prematurely truncated 
at the end of exon 4. Transcript B retains the first DM10 domain 
(see Figure 2 for an illustration of EFHC1). Transcript B is not 
expressed in the mouse brain, but it is expressed in human and 
chimpanzee neural tissue. Transcripts C and D have not been 
evaluated for their role in epilepsy or their expression in other 
mammalian species.
Cosegregation
Of 33 putative pathogenic variants, eight were reported to cose-
gregate with 40 clinically and EEG polyspike wave–affected 
family members across two to four generations of 12 JME fami-
lies in four separate cohorts from Mexico, Honduras, Italy, and 
Tennessee (USA).16,17,19,23 The remaining variants were detected 
only in singletons (Table 1).
Table 1 summarizes the pedigrees studied and calculates 
the estimated penetrances within and across all families. We 
reanalyzed the patterns of cosegregation with JME and the EEG 
polyspike wave trait in affected carrier families and calculated 
a Bayesian method for evaluating causality of variants29 using 
eight EFHC1 variants as markers (Table 1). Our reanalysis 
identified the following variants as 3.07- to 1,000-times more 
likely (LOD: 0.4874 to 3.0300) to have cosegregation occur not 
by chance. P77T/R221H (as a double heterozygous variant), 
R221H, R118C, R221H, D253Y, F229L, and Q277X were iden-
tified as single autosomal dominant heterozygous variants.
The families in which R353W and D210N were found were 
too small and hence underpowered to detect significant link-
age. P77T/R221H and trB:Q277X both had LOD scores >2.0 





















Y33H Index4a25 3 0 0 0 1.0000 1.0000 0.3106 2.04
P77T/R221H Mexico116 2 3 1 4 0.3333 0.8333 1.9492 88.97
Mexico216 2 1 1 0 0.5000 0.7500 0.3016 2.00
Total 4 4 2 4 0.4000 0.8000 2.2509 178.19
R118C MexicoA18 3 0 0 1 1.0000 1.0000 0.4874 3.07
D210N Mexico516 2 1 1 0 0.5000 0.7500 −0.0350 0.92
R221H TN123 2 0 2 1 0.5000 0.5000 0.7791 6.01
Totala 6 4 4 5 0.4286 0.7143 3.0300 1,071.43
F229L Mexico316 2 1 0 0 0.6667 1.0000 0.3004 2.00
Mexico416 3 2 2 4 0.4286 0.7143 0.5998 3.98
Italy1319 2 0 1 0 0.6667 0.6667 1.0155 10.36
Total 7 3 3 4 0.5385 0.7692 1.9157 82.35
D253Y Mexico616 2 0 0 1 1.0000 1.0000 0.4874 3.07
Q277X Honduras1517 4 5 5 14 0.2857 0.6429 2.4434 277.59
R353W Italy2519 3 0 0 0 1.0000 1.0000 −0.0489 0.89
R353Q Index4b25 1b 0 3 3 – – −4.9308 1.17E-05
P429P Italy419 2b 0 0 – – −2.2438 0.01
Total (across all IBD 
cosegregating variants)
30 13 13 25 0.5357 0.7679
The pedigrees are summarized here as they were originally published with counts of clinically affected individuals, clinically asymptomatic individuals with SW/PSW EEG 
traits, asymptomatic carriers of EFHC1 variants with no observed EEG traits, and noncarrier family members. Estimates of “clinical” and “clinical and EEG trait” penetrances 
were calculated for each family and across each variant.
aThe total data for the R221H variant also include the Mexico1 and Mexico2 families in which the variant was found in a double heterozygous haplotype with P77T/R221H. 
bR353Q cosegregates with only one of the four affected members in this family. P429P segregated with only two of the three affected members in this family.
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(pathogenic OR >100×), which is suggestive of linkage. R221H 
(including in the two families where it was found with P77T) 
had a LOD score >3.0, which is significant for linkage. Our 
reanalysis does not show whether the combination of P77T and 
R221H produces a disruption of EFHC1 function or whether 
R221H by itself is causal.
One reported variant, P429P, segregated with two out of three 
affected individuals in a family from Italy, and presumptively in 
trans with the nonpathogenic variant R182H, which segregated 
with all three affected individuals.19 The Bayesian LOD score for 
this variant was −2.2438. Another variant, R353Q, cosegregated 
with one of the four clinically affected members in the family25 
with a Bayesian LOD score of −4.9308. These variants meet the 
“strong” criterion (BS4) for benign status.
Our reanalysis of cosegregating families indicated that 
EFHC1 variants were transmitted in an autosomal dominant 
manner and suggested the implication of EFHC1 variants in 
JME. In weighing the value of cosegregation as ACMG eviden-
tiary data, we first considered it as only “supporting” evidence 
for pathogenicity because it is not clear from ACMG guidelines 
how to weight evidence of cosegregation in one large multi-
generational family. However, because there was increasing 
segregation data in at least seven families from diverse ethnic 
backgrounds, these cosegregation data could be weighed by 
ACMG as moderate to strong evidence.3
Case association studies
The 12 case–control association studies yielded 32 putative 
pathogenic variants (note: R276X was not studied in case–
controls) (Table 2 and Supplementary Table S3 online). An 
additional four variants (L9L, R353P, E357K, and P429P) were 
originally published as polymorphisms, because they either 
were found in one control or produced a synonymous change 
in the protein product. These four variants were found to be 






JME GGEs OR P value
Pathogenic variants
229C>A P77T
Latino 2 64 – – 0 504 ∞ 0.0043 **
Latino 0 46 0 92 1 120 0 1
African – – 0 34 2 46 GGE 0 1
628G>A D210N
Latino 1 64 – – 0 504 ∞ 0.0467 *
662G>A R221H
Latino 2 64 – – 0 504 ∞ 0.0043 **
Latino 0 46 0 92 1 120 0 1
African – – 0 34 2 46 GGE 0 1
Caucasian 1 108 – – 0 240 ∞ 0.1396
685T>C F229L
Latino 2 64 – – 0 504 ∞ 0.0043 **
Caucasian – – 1 184 0 206 GGE ∞ 0.2425
Caucasian 2 54 – – 0 100 ∞ 0.0469 *
Caucasian ‡ 48 ‡ 122 4 736 ‡ ‡
South American 3 204 – – 0 100 ∞ 0.1827
Caucasian 2 76 – – – – – –
829C>T Q277X
Latino 2 88 – – 0 1,246 ∞ 0.0013 **
757G>T D253Y
Latino 1 64 – – 0 504 ∞ 0.0467 *
OR of “∞” occurred when the variant was not detected in controls. P values for each were calculated using an unconditional exact test (Z-pooled, one-tailed) for results 
within the study only.
‡Syndrome-specific allele counts were not provided in the referenced paper. Moreover, other epilepsy patients (e.g., temporal lobe epilepsy) were included in the cohort. For 
these reasons, specific risk for JME or GGE could not be calculated.
*P value <0.05. **P value <0.01.
GGE, genetic generalized epilepsy; JME, juvenile myoclonic epilepsy; OR, odds ratios.
Genetics in medicine
7EFHC1 variants according to NHGRI and ACMG guidelines  |  BAILEY et al SyStematic Review
absent in their race-matched population in ExAC.14 The final 
variant included in Supplementary Table S3 online is R159W, 
which has been reported as benign in nearly all studies but 
reached statistical significance during case association within 
two studies. It should be noted that the variant was no longer 
significant when compared with the ExAC population data. For 
each variant, all studies that genotyped the variant in a case or a 
control are summarized in Table 2 and all details are presented 
in Supplementary Table S3 online.
Within the scope of their specific study design, nine vari-
ants reached statistical significance and had an OR >5: P77T, 
D210N, R221H, F229L, trB: G264Vfs*280, trB:Q277X, T252K, 
D253Y, and c.*91T>C. When using the race-matched ExAC 
population data, all of the variants listed here still reached sta-
tistical significance within their own study, and an additional 
18 variants also met the ACMG criterion for strong evidence 
(PS4). Three variants were replicated and met the criterion in 
two or more studies: R221H, F229L, and R353W.
Allele frequencies
Eight variants were completely absent across all popula-
tions in the ExAC database: C259Y, R276X, E322K, K378E, 
A394S, P429P, c.1640+1G>A, and c.*91T>C (Supplementary 
Table S4a,b online). Another eight variants were absent in the 
race-matched subpopulation in ExAC: L9L, R118C, R152Q, 
I174V, T252K, R353P, E357K, and Y485H. Two additional vari-
ants were absent in the race-matched European American sub-
population of the ESP6500si database: R221H and R353W.
Of the 54 variants we examined, 17 were found at allele fre-
quencies greater than the expected population prevalence: 
P77T, H89R, R182C, D210N, R221H (only in the Latino sub-
population), F229L, trB:G264Vfs, trB:Q277X, R294H, R353W, 
R436C, M448T, T508R, N607N, I619S, and Y631C. The 
ESP6500si database corroborated only three of these variants as 
being greater than the population prevalence: F229L, M448T, 
and R294H. Finally, six variants met the stand-alone BA1 crite-
ria based on their allele frequency in ExAC: c.-148_147delGC, 
R159W, R182H, c.573+10A>G, I619L, and c.*121C>A. ExAC 
and ESP6500si do not target intronic regions, so certain vari-
ants do not have allele frequencies. 1000 Genomes identifies 
two additional intronic variants, c.1492+175_176delTT and 
c.1851+59C>T, that were at allele frequencies >0.05.
In silico analysis for conservation and damaging effects
All exonic variants, except the two transcript B variants, were 
predicted to be evolutionarily constrained across a phylogeny 
of species by at least one nucleotide conservation measure 
(Supplementary Table S5a–c online). None of the conserva-
tion scores predicted either of the transcript B variants to be 
conserved across species. This is predictable because transcript 
B was not found to be expressed in the mouse brain, but it was 
expressed in humans and chimpanzees; therefore, it may not 
be under evolutionary constraint across the entirety of the 
vertebrate or mammalian clades. V556L was not found to be 
conserved by any of the nucleotide-based calculations, but it 
was determined to be part of a conserved element by GERP++ 
spanning exon 10.
Eight exonic variants were predicted to be benign by all eight 
pathogenicity algorithms: P77T, R221H, R353P, E357K, A394S, 
M448T, K378E, and V556L. Of these variants, only P77T and 
R221H underwent experimental functional testing and were 
found to have a significant effect on several measures of cal-
cium channel–dependent activities and neurodevelopment 
(see Results and Discussion, and Supplementary Table S6a,b 
online). The other variants that showed similar significant dif-
ferences in functional experiments were D253Y (predicted to 
be pathogenic by five of the algorithms), D210N (predicted to 
be pathogenic by seven), and F229L (predicted to be patho-
genic by four algorithms). The only variant that was predicted 
to be pathogenic by all eight measures—the ACMG require-
ment for “supporting” pathogenic evidence (PP3)—was R436C. 
It should be noted that the FATHMM algorithm predicted all 
but one of the variants to be benign. Five variants were found as 
the reference allele in two or more mammalian species: R221H, 
R296H, M448T, and Y355C, which meets the requirement for 
“supporting” benign evidence (BP4).
Human Splice Finder results are summarized in 
Supplementary Table S5c online. Ten variants were pre-
dicted to create new donor or acceptor sites, and one variant 
(c.1640+1G>A) disrupted the wild-type donor sites. Thirty-one 
variants were predicted to disrupt splicing enhancer motifs, 
and 17 variant were predicted to create new splicing silencer 
motifs. Eight variants were predicted to not alter the splicing 
consensus by any of the algorithms. We applied the PP3 and 
BP4 criteria only to synonymous variants and those affecting 
canonical splicing sites.
Variant-specific experimental evidence for pathogenicity
Only a few variants of EFHC1 have undergone functional test-
ing (Supplementary Table S6a–c online). Five EFHC1 vari-
ants were originally reported in JME patients from Mexico16 
(P77T, D210N, R221H, F229L, and D253Y), in reverse TRPM2-
induced (transient receptor potential calcium permeable M2 
channel) apoptosis, and in current densities.57 Four of these vari-
ants (the exception was P77T, which was not tested) produce 
severe mitotic spindle defects during cell division55 and impair 
early radial and tangential migration of neuroblasts,56 thus pro-
viding experimental evidence that EFHC1 variants are damag-
ing to gene function. Supplementary Table S6a,b online show 
the published statistical results of 14 experimental measures 
demonstrating a significant difference between the tested vari-
ants and the wild-type protein. Three variants (R159W, R182H, 
and I619L) classified as benign polymorphism did not produce 
statistically significant results in almost all of the measures in 
comparison to the wild type.16,55–57 R182H showed a small, but 
significant difference in apoptotic activity in primary mouse 
hippocampal neurons in culture.16
Most recently, Sahni et al.58 demonstrated that wild-type 
EFHC1 proteins interacted with products of 16 genes. Of the 
EFHC1 disease alleles tested, R221H and A394S perturbed 
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Table 3 Combination of evidentiary data, their weight, and strength of evidence used to classify variants into the five-tier 
American College of Medical Genetics and Genomics classification of sequence variants
Nine pathogenic variants
c.229C>A p.P77T
Strong •  Experimental functional studies show damaging effect on function or dominant/negative effect on calcium signaling and apoptosis. 
Perturbed 15 of 16 protein–protein-interactions (PPIs) detected in the EFHC1-WT (Edgetic).
•  Prevalence significantly increased in JME over both study controls (OR: ∞; P = 0.0043) and ExAC population rates (OR: 19.61;  
P = 0.0140)
Support •  Found to cosegregate with four clinically affected and four asymptomatic SW-affected individuals in two families  
(Bayesian LOD score: 2.2509)
Benign • MAF in ExAC is greater than expected for the disorder
c.628G>A p.D210N
Strong •  Experimental functional studies show damaging effect on function or dominant/negative effect on calcium signaling, apoptosis, and 
neuroblast migration
•  Prevalence significantly increased in JME over both study controls (OR: ∞; p = 0.0467) and ExAC population rates (OR: 26.23;  
P = 0.0244)
Support •  Found to cosegregate with two clinically affected and one asymptomatic SW-affected individuals in one family (Bayesian LOD score: 
−0.0350)
Benign • MAF in ExAC is greater than expected for the disorder
c.662G>A p.R221H
Strong •  Experimental functional studies show damaging effect on function or dominant/negative effect on calcium signaling, apoptosis, and 
neuroblast migration. Perturbed all 16 protein–protein interactions detected in the EFHC1-WT (quasi-null)
•  Prevalence significantly increased in JME over both study controls (OR: ∞; P = 0.0043) and ExAC population rates in two studies  
(OR: 18.63, P = 0.0036; OR: 311.84, P = 0.0006)
Moderate • Absent in European Americans in ESP6500si
Support •  Found to cosegregate with six clinically affected and four asymptomatic SW-affected individuals in three families  
(Bayesian LOD score: 3.0300)
Benign • MAF in ExAC is greater than expected for the disorder (for Latinos)
• Found as reference allele in 4 out of 62 mammalian species
c.685T>C p.F229L
Strong • Experimental functional studies show damaging effect on function or dominant/negative effect on calcium signaling and apoptosis
•  Prevalence significantly increased in JME over both study controls in two studies (OR: ∞, P = 0.0043; OR: ∞, P = 0.0469) and ExAC 
population rates in three studies (OR: 16.94, P = 0.0041; OR: 8.43, P = 0.0074; OR: 5.89, P = 0.0159)
Support •  Found to cosegregate with seven clinically affected and three asymptomatic SW-affected individuals in three families (Bayesian LOD 
score: 1.9157)
Benign • MAF in ExAC and ESP6500si is greater than expected for the disorder
trB: c.829C>T trB: p.Q277X
Strong • Found de novo in clinically affected patient with paternity and maternity confirmed
•  Prevalence significantly increased in JME over both study controls (OR: ∞; P = 0.0043) and ExAC population rates (OR: 19.61;  
P = 0.0140)
Moderate • Stop-gain mutation truncating the final residue in the transcript
Support •  Found to cosegregate with four clinically affected and five asymptomatic SW-affected individuals in one family (Bayesian LOD score: 
2.4434)
Benign • MAF in ExAC is greater than expected for the disorder
c.757G>T p.D253Y
Strong • Found de novo in clinically affected patient with paternity and maternity confirmed
•  Prevalence significantly increased in JME over both study controls (OR: ∞; P = 0.0043) and ExAC population rates (OR: 19.61;  
P = 0.0140)
Support •  Found to cosegregate with four clinically affected and five asymptomatic SW-affected individuals in one family (Bayesian LOD score: 
2.4434)
c.826C>T p.R276X
Very strong • Nonsense mutation causing the deletion of six exons of the protein
Moderate • Absent in all populations in the ExAC and ESP6500si
• Protein length changes due to in-frame deletions/insertions in a nonrepeat region or stop-loss variants
c.1180G>T p.A394S
Strong • Perturbed all 16 protein–protein-interactions detected in the EFHC1-WT (quasi-null)
• Prevalence significantly increased in GGEs over ExAC population rates (OR: ∞; P = 2.59E-05)
Moderate • Absent in all populations in the ExAC and ESP6500si
ExAC, Exome Aggregation Consortium; GGE, genetic generalized epilepsy; JME, juvenile myoclonic epilepsy; OR, odds ratios.
Table 3 Continued
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c.1640 + 1G>A
Very strong • Null variant disrupting the canonical +1 splice site at the end of exon 9
Strong • Prevalence significantly increased in JME over ExAC population rates (OR: ∞; P = 0.0015)
Moderate • Absent in all populations in the ExAC and ESP6500si
Support • Predicted to break the WT donor site by Human Splicing Finder
14 likely pathogenic variants
c.25T>C p.L9L
Strong • Prevalence significantly increased in JME over ExAC population rates (OR: ∞; P = 1.10E-07)
Moderate • Absent in Europeans in ExAC and European Americans in ESP6500si
Support • Human Splice Finder predicted the variant to alter the WT splicing consensus
c.352C>T p.R118C
Strong • Prevalence significantly increased in JME over ExAC population rates (OR: ∞; P = 0.0027)
Moderate • Absent in Latinos in ExAC.
Support • Found to cosegregate with three clinically affected individuals in a small family (Bayesian LOD score: 0.4874)
c.458G>A p.R153Q
Strong • Prevalence significantly increased in JME over ExAC population rates (OR: 70.83; P = 0.0097)
Moderate • Absent in Latinos in ExAC.
c.520A>G p.I174V
Strong • Prevalence significantly increased in GGEs over ExAC population rates (OR: ∞; P = 2.61E-05)
Moderate • Absent in Europeans in ExAC and all populations in ESP6500si
trB: c.786delA trB: p.G264Vfs
Strong •  Prevalence significantly increased in JME over both study controls (OR: ∞; P = 0.0260) and ExAC population rates (OR: 14.57;  
P = 0.0174)
Moderate • Frameshift deletion altering the final 16 residues in the transcript
Benign • MAF in ExAC is greater than expected for the disorder
c.755C>A p.T252K
Strong • Prevalence significantly increased in JME over both study controls (OR: ∞; P = 0.0260) and ExAC population rates (OR: ∞; P = 0.0028)
Moderate • Absent in Latinos in ExAC
c.776G>A p.C259Y
Strong • Prevalence significantly increased in GGEs over ExAC population rates (OR: ∞; P = 2.61E-05)
Moderate • Absent in all populations in the ExAC and ESP6500si
c.964G>A p.E322K
Strong • Prevalence significantly increased in JME over ExAC population rates (OR: ∞; P = 2.61E-05)
Moderate • Absent in all populations in ExAC
c.1057C>T p.R353W
Strong • Prevalence significantly increased in JME over ExAC population rates in two studies (OR: 50.33, P = 0.0021; OR: 6.27, P = 0.207)
Moderate • Absent in European Americans in ESP6500si
Support • Found to cosegregate with three clinically affected individuals in a family (Bayesian LOD score: −0.0489)
Benign • MAF in ExAC is greater than expected for the disorder
c.1058G>C p.R353P
Strong • Prevalence significantly increased in JME over ExAC population rates (OR: ∞; P = 1.23E-05)
Moderate • Absent in Latinos in ExAC
c.1069G>A p.E357K
Strong • Prevalence significantly increased in JME over ExAC population rates (OR: ∞; P = 2.29E-05)
Moderate • Absent in Europeans in ExAC and European Americans in ESP6500si
c.1132A>G p.K378E
Strong • Prevalence significantly increased in JME over ExAC population rates (OR: ∞; P = 0.0212)
Moderate • Absent in all populations in ExAC
c.1453T>C p.Y485H
Strong • Prevalence significantly increased in JME over ExAC population rates (OR: ∞; P = 0.0198)
Moderate • Absent in South Asians in ExAC
c.*91T>C
Strong •  Prevalence significantly increased in JME over both study controls (OR: ∞; P = 0.0231) and ExAC population rates (OR: ∞; P = 0.0009)
Moderate • Absent in all populations in ExAC
ExAC, Exome Aggregation Consortium; GGE, genetic generalized epilepsy; JME, juvenile myoclonic epilepsy; OR, odds ratios.
Table 3 Continued on next page
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EFHC1 interaction with all 16 genes. P77T disrupted interaction 
with all but one protein (TEX11, which is expressed exclusively 
in male germ cells and therefore may not play a role in epilep-
togenesis), and T508R disrupted interaction with four proteins. 
The PPI profiles of the two polymorphisms, R159W and M448T, 
did not show any significant perturbation of the wild-type net-
work (see Supplementary Table S6c online for summary of 
these findings). Interactions with five gene products—CCDC36 
(Coiled-coil Domain Containing 36), EIF4ENIF1 (Eukaryotic 
Translation Initiation Factor 4E Nuclear Import Factor 1), REL 
(V-Rel Avian Reticuloendotheliosis Viral Oncogene Homolog), 
TCF4 (Transcription Factor 4), and ZBED1 (Zinc-Finger, BED 
containing 1)—were interrupted by all four of the EFHC1 dis-
ease alleles. Four of these proteins—EIF4ENIF1, REL, TCF4, 
and TRAF2—play important roles in the regulation of neuron-
specific differentiation or apoptosis.62–65 Two of the interactors, 
GOLGA2 and ZBED1, have been implicated in cell-cycle con-
trol and cell proliferation.66,67 TRIP6 is a positive regulator of 
lysophosphatidic acid (LPA)-induced cell migration.68 Finally, 
three of the proteins whose interactions were perturbed—REL, 
TRAF2, and TRIP6—play roles in the NF-κB signaling pathway 
and have been implicated in the processes of hippocampal syn-
aptic plasticity and memory.69
Gene-level experimental evidence for pathogenesis
Supplementary Table S7 online summarizes 20 gene-level 
experimental studies of efhc1-deficient mouse59,60 and fly 
 models.61 The most impressive experimental evidence for dis-
ease causality seeing the epileptic disorder manifest in a knock-
out animal model. Supplementary Video S1 online shows an 
efhc1KO mouse (efhc1−/−) having several massive myoclonias 
and a CTC convulsion.60 The massive myoclonic seizures and 
CTC convulsions shown in the video can occur in homozygous 
efhc1−/− and heterozygous efhc1+/− mutant mice.
Heterozygous (efhc1+/−) and null (efhc1−/−) mutants exhibit 
more spontaneous positive myoclonias than wild-type mice 
and quick, high-amplitude polyspikes on their EMG.59 Two 
measures of seizure susceptibility—the percentage of animals 
exhibiting generalized seizures within 600 s after treatment 
with pentylenetretrazole (PTZ) and latency to clonic seizures 
after PTZ treatment—are significantly increased in the same 
measures of wild-type mice, with the greatest significance 
reached in 9- to 12-month-old mice. Both efhc1+/− and efhc1−/− 
mutant mice show ependymal cilia in the lateral ventricles, with 
abnormally decreased movements at 3 months and slightly 
enlarged lateral ventricles and decreased hippocampal volume 
at 12 months.59 In mice with massive myoclonias and grand mal 
CTC convulsions, cell death occurs in ependymal cells along 
periventricular zones (both lateral and fourth ventricles) and in 
striatal cells, while disorganization of cell layering in paraven-
tricular nucleus of hypothalamus, thalamus, hippocampus, and 
neocortex is present.60
The notion of overgrown and overexcitable neurons and 
neurites was further examined in vivo in Drosophila mela-
nogaster.61 Knocking out the Drosophila DEFHC1.1 gene, a 
homolog of human EFHC1, resulted in supernumerary syn-
aptic boutons at the neuromuscular junction synapse and 
increased terminal branching of dendritic arborization, along 
with increased spontaneous neurotransmitter release. The 
notion of overgrown and overexcitable neurons and neurites 
was further solidified when DEFHC1.1 overexpression rescued 
and markedly reduced dendrite branching and complexity.61 
These rescue experiments strongly recommended by NHGRI 
core guidelines argue convincingly that EFHC1’s main func-
tion is to restrain excessive synaptic and dendritic growth and 
arborization.
DISCUSSION
In research laboratories, the primary purpose of the search 
for disease-associated variants is to identify molecular disease 
mechanisms that can lead to a quest for a curative molecule.1 
During clinical laboratory testing, however, the primary pur-
pose of searching for disease-causing sequence variants is to 
support medical decision making.3 Here, in the reanalysis of 
EFHC1 variants, we search for disease mechanisms that pro-
duce the most feared and most neurologically damaging seizure 
phenotype—the grand mal CTC convulsions of JME—while we 
weigh evidence for or against pathogenicity of a given EFHC1 
variant that can be used in medical decision making.
Applying NHGRI guidelines and ACMG classification to all 
54 EFHC1 variants in literature, we show that EFHC1 is defi-
nitely implicated in JME. Table 2 provides evidence used to 
classify all the variants as “pathogenic” and “likely pathogenic.” 
Supplementary Table S8a online summarizes the ACMG cri-
teria used for classifying all 54 EFHC1 variants included in 
this study. Using ACMG combinatorial criteria, we classified 9 
EFHC1 variants as “pathogenic,” 14 variants as “likely patho-
genic,” and 20 variants “of unknown significance” (Table 3). 
Eight EFHC1 variants were benign and 3 were likely benign.
Of the “pathogenic” variants, the five original EFHC1 variants 
discovered in Mexican families16 met two “strong” criteria for 
pathogenicity; they were found to be statistically increased in 
JME cases in comparison to controls in at least one study and 
also demonstrated a significant difference in 4 to 10 experimen-
tal measures of neuron function and neurodevelopment.55–57 
trB:Q277X was found to be statistically increased in disease cases 
compared with controls, and it was found de novo in a singleton 
whose parentage was confirmed.17 R276X, a nonsense variant 
that truncates the final six exons of the primary transcript, was 
associated with a JME patient and reported in the ClinVar data-
base.15 It was also found as a de novo mutation in a single case of 
epileptic encephalopathy (personal  communication during pre-
sentation of a poster by S. Jamuar et al. during 2013 American 
Epilepsy Society Meeting.), thereby meeting the ACMG “very 
strong” criteria for pathogenicity (PVS1).
Within the scope of their originally reported individual stud-
ies, 20 EFHC1 variants did not reach statistical significance 
during case–control association because these studies, having 
an insufficient number of racial/ethnic- and ancestry-matched 
controls, were statistically underpowered. However, when 
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compared with racial/ethnic-matched ExAC population con-
trols, these same EFHC1 variants have ORs >5 and reach sta-
tistical significance.
Fourteen variants classified as “likely pathogenic” would have 
been classified as “unknown” if only the results within their spe-
cific case–control study were used. Although most of these vari-
ants were absent in the study controls run, two variants—L9L 
and E357K—were found in the study ancestry-matched con-
trols but were completely absent from Europeans in ExAC.14 
These variants may be examples of population-specific benign 
variations whose case association would have resulted in false 
positives if the ancestry-matched population controls were not 
included in the study and only the public genome databases 
were used as reference panels. These observations demon-
strate the necessity of using both (i) study controls, matched 
for ancestry and country of residence, who are well screened to 
be free of epilepsy and febrile convulsions in their families and 
(ii) large public genome databases that have not been screened 
for epilepsy.
In the framework of the larger population groups used by 
ExAC,14 we attempted to quantify the statistical effect size that 
pathogenic variants would have on JME patients. These esti-
mates were calculated using the number of JME index cases in 
each population group who were screened for variants in all 
exons of EFHC1 (see Supplementary Table S2 online). Among 
Latinos, variants meeting the ACMG standard of “pathogenic” 
were identified as heterozygous mutations in 4.10% of indi-
viduals with JME, and “likely pathogenic” variants were found 
in another 3.59%. In Caucasians, both “pathogenic” and “likely 
pathogenic” variants were discovered in 2.59% (each) of indi-
viduals with JME. Currently, the variants discovered in India 
only meet the standard for “likely pathogenic” and account for 
1.46% of all its screened JME patients.28 However, we are still 
awaiting publication of experimental functional studies of the 
EFHC1 variants discovered in JME patients in India. These 
studies will probably change their classification. Finally, the 
JME cohort from Brazil found variants meeting the “patho-
genic” standard in only 2.94% of their JME cases (unpublished 
observations).
Further evidence for a large effect on the phenotype of JME 
is provided by a nonconsanguineous Moroccan-Jewish fam-
ily in which three of their seven children afflicted with intrac-
table epilepsy during infancy and who died at 18–36 months.24 
Whole-exome sequencing of the family revealed a homozygous 
mutation of F229L in two of the three affected children (the 
third child could not be tested). These children began experi-
encing seizures 6–12 h after birth and subsequently developed 
severe psychomotor retardation and microcephaly. Brain MRI 
of one of the children at 2 years of age exhibited decreased cer-
ebellar volume, hypomyelination, and enlarged lateral and third 
ventricles, consistent with both our variant-specific experiments 
and gene-level experiments in knockout models of EFHC1 
(efhc1−/− KO mice and the loss-of-function fly model).
When a variant’s allele frequency and its population 
prevalence are greater than the disease prevalence, ACMG 
recommendations consider this result “strong” criterion for the 
benign status for the variant. This criterion needs to be revisited 
by the AMG workgroup and rediscussed in the context of non-
monogenic disorders because of the uncertainty of the preva-
lence of specific diseases such as a specific epilepsy syndrome 
like JME. Although this criterion did not change the pathogenic 
classification of EFHC1 variants in question according to the 
combinatorial rules of ACMG, 5 of the 7 “pathogenic” variants 
and 2 of the 16 “likely pathogenic” variants were found to have 
allele frequencies higher than the expected prevalence of the 
JME in their respective populations. There are three possible 
explanations for this observation:
1. The population prevalence studies are poorly matched to 
the populations in which the variants were found. Most 
epidemiology studies focused only on the prevalence of 
“active” epilepsies, a measure that is important for pub-
lic health policy and estimation of economic impact. 
However, the lifetime prevalence, which would attempt to 
also capture individuals with a history of epilepsy prior to 
the date of ascertainment but who may be in remission or 
no longer seeking treatment, would be a better measure 
for comparison in genetic studies. Furthermore, studies 
of epilepsy prevalence frequently do not capture further 
information of seizure types or classifications of electro-
clinical syndromes. When they do, different diagnostic 
and ascertainment criteria make it difficult to compare 
results between studies.
2. The ExAC database, our primary reference panel for 
estimating minor allele frequencies, includes exomes of 
several disease populations. Notably, these three studies 
were targeted toward the identification of neurological 
diseases such as schizophrenia and Tourette syndrome. 
Although EFHC1 has not been specifically implicated 
in either of these conditions, other genes implicated in 
JME and childhood absence epilepsy show overlap with 
those implicated in schizophrenia, specifically GABRA1, 
GABRB3, GABRG2 (refs. 70,71), and CHRNA7 (ref. 72), 
indicating that the ExAC database may be enriched with 
these alleles.
3. Like variants associated with other diseases that have a 
complex genetic architecture, some EFHC1 variants may 
not be sufficient by themselves to cause epilepsy; however, 
they may have an additive effect toward the pathogenesis 
of JME disease in conjunction with other alleles associ-
ated with epilepsy. This would also explain the discovery 
of JME disease alleles in screened study controls20,21 as 
well as in the case of multiple disease alleles in linkage 
disequilibrium and the autosomal dominant transmis-
sion with incomplete penetrance that we see in our large 
families.
In the case of a fully penetrant monogenic disease with a 
large statistical effect size (the disease model used when creat-
ing both the NHGRI and ACMG standards), the comparison 
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of allele frequencies to population prevalence may provide an 
appropriate guideline for classifying diseases. However, genetic 
cases of JME exhibit a high degree of phenotypic heterogene-
ity, and even within the affected families only 50.94% of all 
heterozygous carriers actually develop clinical epilepsy. Of all 
the implicated JME genes, EFHC1 has been replicated by more 
studies than any other, but “pathogenic” and “likely patho-
genic” variants still only account for approximately 3% of JME 
cases in Caucasians and 8% of those in Hispanics. JME does not 
perfectly fit the disease model for which these standards were 
created. However, even with this limitation, the ACMG and 
NHGRI guidelines enabled us to classify the purported disease-
causing variants in EFHC1.
In conclusion, we found the NHGRI and ACMG guidelines 
to be useful in quantifying the amounts and types of evidence 
that implicate sequence variants of EFHC1 as disease-causing in 
JME. Vetting EFHC1 variants through NHGRI guidelines1 defi-
nitely implicates these EFHC1 variants in JME. Using ACMG 
recommendations, scoring rules, and combinatorial criteria to 
choose a classification from the five-tier system,3 our reanalysis 
showed that 9 EFHC1 variants are “pathogenic,” 14 are “likely 
pathogenic,” and 20 are “variants of unknown significance.” (See 
Supplementary Table S8b online for criteria and classification 
of all variants.) NHGRI gene-level evidence and variant-level 
evidence establish EFHC1 as the first non–ion channel micro-
tubule–associated protein53 whose mutations disturb R-type 
VDCC16 and TRPM2 calcium currents57 in overgrown synapses 
and dendrites61 within abnormally migrated dislocated neu-
rons,56 thus explaining myoclonic and grand mal CTC convul-
sions and “microdysgenesis”73,74 neuropathology of JME.
SUPPLEMENTARY MATERIAL
Supplementary material is linked to the online version of the paper 
at http://www.nature.com/gim
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